| 1 | Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study. (Jindal T, Jiang CY, Alhalabi O, Davidsohn M, Freeman D, Epstein IY, Bakaloudi DR, Talukder R, Nizam A, Nguyen CB, Oh E, Tsung I, Glover MJ, Khaki AR, Taylor AK, Jaime-Casas S, Jang A, Lemke E, Pywell C, Evans ST, Shin D, Bilen MA, Basu A, Kilari D, Tripathi A, Brown J, Emamekhoo H, Davis NB, Shah S, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS) Urol Oncol 2026 Jan;44(1):65.e1-65.e11 |
| 1 | Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data. (Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, Bakaloudi D, Davidsohn M, Freeman D, Glover M, Khaki AR, Evans S, Lemke E, Bose R, Sim W, Pywell C, Basu A, Kilari D, Barata PC, Bilen MA, Zakharia Y, Milowsky MI, Shah SA, Bellmunt J, Grivas P, Emamekhoo H, Davis NB, Gupta S, Hoimes C, Campbell MT, Alva A, Koshkin VS) Eur Urol Oncol 2025 Apr;8(2):258-262 7 Citations |
| 1 | A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomy. (de Jong JJ, Proudfoot JA, Daneshmand S, Svatek RS, Narayan V, Gibb EA, Davicioni E, Joshi S, Dahmen A, Li R, Inman BA, Shah P, Chaplin I, Wright J, Lotan Y) BJU Int 2025 Apr;135(4):648-656 3 Citations |
| 1 | Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. (Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS) Cancer 2022 Mar 15;128(6):1194-1205 76 Citations |
| 1 | Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy. (Winters BR, De Sarkar N, Arora S, Bolouri H, Jana S, Vakar-Lopez F, Cheng HH, Schweizer MT, Yu EY, Grivas P, Lee JK, Kollath L, Holt SK, McFerrin L, Ha G, Nelson PS, Montgomery RB, Wright JL, Lam HM, Hsieh AC) JCI Insight 2019 May 30;5(13) 38 Citations |
| 1 | Patterns of Urachal Remnant Involvement by Urothelial Carcinoma: Intraluminal Noninvasive Spread Can Mimic a Deep-seated Bladder Invasion. (Han L, Gallan A, Paner GP) Am J Surg Pathol 2019 Apr;43(4):475-479 6 Citations |
| 1 | Utilization and Outcomes of Nephroureterectomy for Upper Tract Urothelial Carcinoma by Surgical Approach. (Rodriguez JF, Packiam VT, Boysen WR, Johnson SC, Smith ZL, Smith ND, Shalhav AL, Steinberg GD) J Endourol 2017 Jul;31(7):661-665 57 Citations |
| 1 | Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. (O'Donnell PH, Alanee S, Stratton KL, Garcia-Grossman IR, Cao H, Ostrovnaya I, Plimack ER, Manschreck C, Ganshert C, Smith ND, Steinberg GD, Vijai J, Offit K, Stadler WM, Bajorin DF) Clin Genitourin Cancer 2016 Dec;14(6):511-517 5 Citations |
| 2 | The Dose-Response Relationship of bacillus Calmette-Guérin and Urothelial Carcinoma Cell Biology. (Shah G, Zhang G, Chen F, Cao Y, Kalyanaraman B, See WA) J Urol 2016 Jun;195(6):1903-10 13 Citations |
| 1 | A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy. (Di Trapani E, Sanchez-Salas R, Gandaglia G, Rocchini L, Moschini M, Lizee D, Carneiro A, Sivaraman A, Barret E, Rozet F, Galiano M, Bennamoun M, Colombo R, Suardi N, Briganti A, Montorsi F, Cathelineau X) World J Urol 2016 Feb;34(2):207-13 17 Citations |
| 1 | Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma. (Ikeda S, Hansel DE, Kurzrock R) Cancer Treat Rev 2015 Sep;41(8):699-706 14 Citations |
| 1 | Commentary on "Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle." Mertens LS, Fioole-Bruining A, Vegt E, Vogel WV, van Rhijn BW, Horenblas S, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam Hospital, Amsterdam, The Netherlands.: BJU Int 2013; 112(6):72934. doi:10.1111/bju.12109. [Epub 2013 Jun 24]. (See WA) Urol Oncol 2014 Nov;32(8):1350 |
| 1 | Commentary on "Optimal schedule of bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: A meta-analysis of comparative studies." Zhu S, Tang Y, Li K, Shang Z, Jiang N, Nian X, Sun L, Niu Y, Department of Urology Tianjin Institute of Urology, 2nd Hospital of Tianjin Medical University, People's Republic of China.: BMC Cancer 2013; 13:332. doi:10.1186/1471-2407-13-332. (See WA) Urol Oncol 2014 Nov;32(8):1349-50 |
| 3 | H2O2 generation by bacillus Calmette-Guérin induces the cellular oxidative stress response required for bacillus Calmette-Guérin direct effects on urothelial carcinoma biology. (Shah G, Zielonka J, Chen F, Zhang G, Cao Y, Kalyanaraman B, See W) J Urol 2014 Oct;192(4):1238-48 23 Citations |
| 1 | Sperm associated antigen 9 plays an important role in bladder transitional cell carcinoma. (Kanojia D, Garg M, Saini S, Agarwal S, Parashar D, Jagadish N, Seth A, Bhatnagar A, Gupta A, Kumar R, Lohiya NK, Suri A) PLoS One 2013;8(12):e81348 35 Citations |
| 1 | Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. (Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer R, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Al-Hawary M, Smith DC, Hussain M) Cancer 2014 Mar 01;120(5):692-701 96 Citations |
| 2 | iNOS expression and NO production contribute to the direct effects of BCG on urothelial carcinoma cell biology. (Shah G, Zhang G, Chen F, Cao Y, Kalyanaraman B, See WA) Urol Oncol 2014 Jan;32(1):45.e1-9 21 Citations |
| 2 | Loss of bacillus Calmette-Guérin viability adversely affects the direct response of urothelial carcinoma cells to bacillus Calmette-Guérin exposure. (Shah G, Zhang G, Chen F, Cao Y, Kalyanaraman B, See W) J Urol 2014 Mar;191(3):823-9 9 Citations |
| 1 | Commentary on "Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?" Mertens LS, Meijer RP, Kerst JM, Bergman AM, van Tinteren H, van Rhijn BW, Horenblas S, Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands: J Urol 2012;188(4):1108-13 [Epub 2012 Aug 15]. (See WA) Urol Oncol 2013 Jul;31(5):716-7 2 Citations |
| 1 | Commentary on "Plasma carotenoids and vitamin C concentrations and risk of urothelial cell carcinoma in the European Prospective Investigation into Cancer and Nutrition." Ros MM, Bueno de Mesquita HB, Kampman E, Aben KK, Büchner FL, Jansen EH, van Gils CH, Egevad L, Overvad K, Tjønneland A, Roswall N, Boutron Ruault MC, Kvaskoff M, Perquier F, Kaaks R, Chang Claude J, Weikert S, Boeing H, Trichopoulou A, Lagiou P, Dilis V, Palli D, Pala V, Sacerdote C, Tumino R, Panico S, Peeters PH, Gram IT, Skeie G, Huerta JM, Barricarte A, Quirós JR, Sánchez MJ, Buckland G, Larrañaga N, Ehrnström R, Wallström P, Ljungberg B, Hallmans G, Key TJ, Allen NE, Khaw KT, Wareham N, Brennan P, Riboli E, Kiemeney LA, National Institute for Public Health and the Environment, Bilthoven, Netherlands: Am J Clin Nutr 2012;96(4):902-10 [Epub 2012 Sep 5]. (See WA) Urol Oncol 2013 Jul;31(5):714-5 |
| 1 | Contributors to HMGB1 release by urothelial carcinoma cells in response to bacillus Calmette-Guérin. (Zhang G, Chen F, Cao Y, See WA) J Urol 2013 Oct;190(4):1398-403 8 Citations |
| 1 | HMGB1 release by urothelial carcinoma cells in response to Bacillus Calmette-Guérin functions as a paracrine factor to potentiate the direct cellular effects of Bacillus Calmette-Guérin. (Zhang G, Chen F, Cao Y, Amos JV, Shah G, See WA) J Urol 2013 Sep;190(3):1076-82 17 Citations |
| 2 | HMGB1 release by urothelial carcinoma cells is required for the in vivo antitumor response to Bacillus Calmette-Guérin. (Zhang G, Chen F, Cao Y, Johnson B, See WA) J Urol 2013 Apr;189(4):1541-6 7 Citations |
| 1 | A synthetic polyvalent ligand for α5β1 integrin activates components of the urothelial carcinoma cell response to bacillus Calmette-Guérin. (Chen F, Zhang G, Cao Y, Wakim B, See WA) J Urol 2013 Mar;189(3):1104-9 4 Citations |
| 1 | A case for routine tonometry to avoid postoperative visual loss. (Usoltsev NA, Shankar H, Zainer CM) Br J Anaesth 2011 Oct;107(4):648-9 2 Citations |
| 1 | The effects of physiological estrogen concentration on the immune response of urothelial carcinoma cells to bacillus Calmette-Guérin. (Guise AI, Chen F, Zhang G, See W) J Urol 2011 Jan;185(1):298-304 4 Citations |
| 2 | MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin. (Chen F, Zhang G, Cao Y, Hessner MJ, See WA) J Urol 2009 Dec;182(6):2932-7 24 Citations |
| 1 | Clinical outcome following prostatic capsule- and seminal-sparing cystectomy for bladder cancer in 25 men. (Thorstenson A, O'connor RC, Ahonen R, Jonsson MN, Wijkstrom H, Akre O, Hosseini A, Wiklund NP, Henningsohn L) Scand J Urol Nephrol 2009;43(2):127-32 11 Citations |
| 1 | Case report: percutaneous management of transitional-cell carcinoma of the upper urinary tract using the bipolar resectoscope. (Storm DW, Fulmer BR) J Endourol 2007 Sep;21(9):1011-3 9 Citations |
| 1 | Bacillus Calmette-Guerin inhibits apoptosis in human urothelial carcinoma cell lines in response to cytotoxic injury. (Chen F, Zhang G, Cao Y, Payne R, See WA) J Urol 2007 Nov;178(5):2166-70 12 Citations |
| 1 | Bacillus Calmette-Guérin induces p21 expression in human transitional carcinoma cell lines via an immediate early, p53 independent pathway. (Zhang G, Chen F, Cao Y, See WA) Urol Oncol 2007;25(3):221-7 10 Citations |
| 1 | Micro-array analysis of the effect of post-transurethral bladder tumor resection urine on transforming growth factor-beta1 dependent gene expression in transitional cell carcinoma. (Zhang G, Cao Y, Xu Y, See WA) Urol Oncol 2005;23(6):413-8 1 Citation |
| 1 | BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking. (Chen F, Zhang G, Iwamoto Y, See WA) BMC Urol 2005 May 12;5:8 50 Citations |
| 1 | Autocrine over expression of fibronectin by human transitional carcinoma cells impairs bacillus Calmette-Guerin adherence and signaling. (Zhang G, Chen F, Xu Y, Cao Y, Crist S, McKerrow A, Iwamoto Y, See WA) J Urol 2004 Oct;172(4 Pt 1):1496-500 4 Citations |
| 1 | Renal infarction secondary to infiltrative transitional cell carcinoma. (Castle EP, Blackford T, Langenstroer P) J Urol 2004 Aug;172(2):477 |
| 1 | Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. (Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G) Cancer 2004 Apr 15;100(8):1639-45 175 Citations |
| 1 | Renal-ovarian axis: a case report and review. (Gavallos G, Tawfik O, Herrell D, Langenstroer P) Urology 2003 Oct;62(4):749 15 Citations |
| 2 | Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines. (Chen F, Langenstroer P, Zhang G, Iwamoto Y, See W) J Urol 2003 Nov;170(5):2009-13 45 Citations |
| 1 | Bacillus Calmette-Guerin initiates intracellular signaling in a transitional carcinoma cell line by cross-linking alpha 5 beta 1 integrin. (Chen F, Zhang G, Iwamoto Y, See WA) J Urol 2003 Aug;170(2 Pt 1):605-10 23 Citations |
| 1 | Interleukin-6 production by human bladder tumor cell lines is up-regulated by bacillus Calmette-Guérin through nuclear factor-kappaB and Ap-1 via an immediate early pathway. (Chen FH, Crist SA, Zhang GJ, Iwamoto Y, See WA) J Urol 2002 Aug;168(2):786-97 38 Citations |
| 1 | Intravesical valrubicin in the treatment of carcinoma in situ of the bladder. (Kuznetsov DD, Alsikafi NF, O'Connor RC, Steinberg GD) Expert Opin Pharmacother 2001 Jun;2(6):1009-13 25 Citations |
| 1 | Autocrine IL-6 production by human transitional carcinoma cells upregulates expression of the alpha5beta1 firbonectin receptor. (Zhang GJ, Crist SA, McKerrow AK, Xu Y, Ladehoff DC, See WA) J Urol 2000 May;163(5):1553-9 28 Citations |
| 1 | Continuous antegrade infusion of adriamycin as adjuvant therapy for upper tract urothelial malignancies. (See WA) Urology 2000 Aug 01;56(2):216-22 14 Citations |
| 1 | Distal ureteral regeneration after radical transurethral bladder tumor resection. (See WA) Urology 2000 Feb;55(2):212-5; discussion 215-6 13 Citations |
| 1 | Airway obstruction due to late-onset angioneurotic edema from angiotensin-converting enzyme inhibition. (Mchaourab A, Sarantopoulos C, Stowe DF) Can J Anaesth 1999 Oct;46(10):975-8 20 Citations |
| 1 | Stable overexpression of TGFbeta1 in a transitional carcinoma cell line: impact on fibronectin production. (Zhang GJ, Ladehoff D, Xu Y, See WA) J Urol 1998 Jul;160(1):230-5 8 Citations |
| 1 | Future therapies for the treatment of bladder neoplasms. (See WA, Berman CJ) Semin Surg Oncol 1997;13(5):376-88 1 Citation |
| 1 | Transurethral bladder tumor resection alters fibronectin expression in transitional carcinoma cell lines. (See WA, Xu Y, Gee K, Severson C, Cohen MB, Ladehoff D) J Urol 1997 Mar;157(3):1136-43 9 Citations |
| 1 | Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. (Dreicer R, Gustin DM, See WA, Williams RD) J Urol 1996 Nov;156(5):1606-8 100 Citations |
| 1 | Annular constriction of the rectum secondary to transitional cell carcinoma of the bladder. (Langenstroer P, Zacharias A, Almagro U, Dewire D) Urology 1996 Mar;47(3):442-4 22 Citations |
| 1 | Histopathological features and p53 nuclear protein staining as predictors of survival and tumor recurrence in patients with transitional cell carcinoma of the renal pelvis. (Terrell RB, Cheville JC, See WA, Cohen MB) J Urol 1995 Oct;154(4):1342-7 32 Citations |
| 1 | Absence of immunohistochemical metallothionein staining in bladder tumor specimens predicts response to neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy. (Bahnson RR, Becich M, Ernstoff MS, Sandlow J, Cohen MB, Williams RD) J Urol 1994 Dec;152(6 Pt 2):2272-5 38 Citations |
| 1 | DNA ploidy and P-glycoprotein expression as predictive factors of response to neoadjuvant chemotherapy for invasive bladder cancer. (Sandlow J, Cohen MB, Robinson RA, Dreicer R, Williams RD) Urology 1994 Jun;43(6):787-91 16 Citations |
| 1 | Diversity and modulation of plasminogen activator activity in human transitional carcinoma cell lines. (See WA, Yong X, Crist S, Hedican S) J Urol 1994 Jun;151(6):1691-6 6 Citations |
| 1 | Regulation of plasminogen activator activity in transitional carcinoma cell lines by wound site growth factors. (Xu Y, See WA) Surg Oncol 1994 Jun;3(3):175-85 3 Citations |
| 1 | Granulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma. (Wetzler M, Estrov Z, Talpaz M, Markowitz A, Gutterman JU, Kurzrock R) J Intern Med 1993 Oct;234(4):417-20 45 Citations |
| 1 | Granulomatous inflammation in bladder wash specimens after intravesical bacillus Calmette-Guerin therapy for transitional cell carcinoma of the bladder. (Betz SA, See WA, Cohen MB) Am J Clin Pathol 1993 Mar;99(3):244-8 26 Citations |
| 1 | Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin: impact of concomitant administration of dimethyl sulfoxide on drug absorption and antitumor activity. (See WA, Xia Q) J Natl Cancer Inst 1992 Apr 01;84(7):510-5 32 Citations |
| 1 | Intravesical recombinant tissue plasminogen activator for the prevention of implantation-mediated bladder tumor recurrence. (See WA) Clin Exp Metastasis 1992 Mar;10(2):99-109 6 Citations |
| 1 | Regional chemotherapy using continuous intravesical infusion doxorubicin for the treatment of muscle invasive transitional cell bladder carcinoma in a rat model. (See WA, Xia Q, McDermott T, Williams RD) J Urol 1991 Oct;146(4):1147-52 3 Citations |
| 1 | Single-dose preoperative systemic cyclophosphamide for the prevention of bladder tumor implantation in F344 rats. (See WA, Crist SA, Boileau MA, Williams RD) Cancer Res 1991 Mar 01;51(5):1373-7 2 Citations |
| 1 | Kinetics of transitional tumor cell line 4909 adherence to injured urothelial surfaces in F-344 rats. (See WA, Chapman PH, Williams RD) Cancer Res 1990 Apr 15;50(8):2499-504 14 Citations |
| 1 | Pathophysiology of transitional tumor cell adherence to sites of urothelial injury in rats: mechanisms mediating intravesical recurrence due to implantation. (See WA, Miller JS, Williams RD) Cancer Res 1989 Oct 01;49(19):5414-8 40 Citations |
| 1 | Heparin prevention of tumor cell adherence and implantation on injured urothelial surfaces. (See WA, Chapman PH) J Urol 1987 Jul;138(1):182-6 43 Citations |
| 1 | Tumor cell implantation following neodymium-YAG bladder injury: a comparison to electrocautery injury. (See WA, Chapman WH) J Urol 1987 Jun;137(6):1266-9 51 Citations |
© 2026 Clinical & Translational Science Institute